About Eukaryotic translation initiation factor 3 subunit G
Eukaryotic translation initiation factor 3 subunit G (EIF3G) is a protein
from Homo sapiens identified by UniProt accession
O75821, 320 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 3 subunit G |
|---|
| UniProt accession | O75821 |
|---|
| Gene | EIF3G |
|---|
| Organism | Homo sapiens |
|---|
| Length | 320 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (28)
Diseases linked to this target (Open Targets).
- narcolepsy-cataplexy syndrome · score 0.43
- neurodegenerative disease · score 0.13
- autism spectrum disorder · score 0.09
- heel bone mineral density · score 0.05
- body height · score 0.04
- ICAM-1 measurement · score 0.03
- lung adenocarcinoma · score 0.03
- neoplasm · score 0.02
- cancer · score 0.02
- Alzheimer disease · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75821-F1 | alphafold | PREDICTED | 70.19 | — |
Amino-acid sequence (320 residues)
MPTGDFDSKP SWADQVEEEG EDDKCVTSEL LKGIPLATGD TSPEPELLPG APLPPPKEVI NGNIKTVTEY KIDEDGKKFK IVRTFRIETR KASKAVARRK NWKKFGNSEF DPPGPNVATT TVSDDVSMTF ITSKEDLNCQ EEEDPMNKLK GQKIVSCRIC KGDHWTTRCP YKDTLGPMQK ELAEQLGLST GEKEKLPGEL EPVQATQNKT GKYVPPSLRD GASRRGESMQ PNRRADDNAT IRVTNLSEDT RETDLQELFR PFGSISRIYL AKDKTTGQSK GFAFISFHRR EDAARAIAGV SGFGYDHLIL NVEWAKPSTN
Explore Eukaryotic translation initiation factor 3 subunit G with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets